Sutetinib maleate

Overview

Sutetinib maleate is the maleate form of Sutetinib ( HY-164387 ). Sutetinib maleate is an orally active inhibitor for tyrosine kinase , that is associated with tumor growth and angiogenesis, such as VEGFR ( K i = 0.009 µM for VEGFR-1/2/3), PDGFR ( K i = 0.008 µM for PDGFR-α/β) and proto-oncogene cKIT . Sutetinib maleate inhibits the proliferation, migration, and tubular structure formation of endothelial cells and fibroblasts, and exhibits board-spectrum antitumor efficacy in vitro and in vivo.

Application

Products | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > EGFR | Products > Signaling Pathways > VEGFR | Products > Signaling Pathways > PDGFR

Product Information

• Catalog No.: HY-164387A
• CAS No.: 1701408-75-4
• Molecular Formula: C30H29N5O6
• Molecular Weight: 555.58
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source